Literature DB >> 28486465

FDA approves PARP inhibitor for ovarian cancer.

.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28486465     DOI： 10.1038/nbt0517-398

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  2 in total

Review 1.  Mutation-Driven Signals of ARID1A and PI3K Pathways in Ovarian Carcinomas: Alteration Is An Opportunity.

Authors:  Pradip De; Nandini Dey
Journal:  Int J Mol Sci       Date:  2019-11-15       Impact factor: 5.923

Review 2.  Novel DNA targeted therapies for head and neck cancers: clinical potential and biomarkers.

Authors:  Mary Glorieux; Rüveyda Dok; Sandra Nuyts
Journal:  Oncotarget       Date:  2017-09-16
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.